Results 131 to 140 of about 72,405 (280)

Early infliximab trough levels in paediatric IBD patients predict sustained remission

open access: yesTherapeutic Advances in Gastroenterology
Background: Exposure–response studies have shown that higher infliximab concentrations are associated with better outcomes in inflammatory bowel disease.
Nanja Bevers   +7 more
doaj   +1 more source

Updated EAACI Statement on Drug Hypersensitivity Skin Testing: Methodology and Non‐Irritative Concentrations

open access: yesAllergy, EarlyView.
ABSTRACT These updated EAACI guidelines aim to standardize skin testing methodologies for both immediate and non‐immediate drug hypersensitivity reactions. For immediate reactions, the optimal testing window is 4–6 weeks post‐reaction; whereas beyond 6 months, false‐negative results increase.
Annick Barbaud   +14 more
wiley   +1 more source

The Impact of Common Medications on Male Fertility: An Updated Systematic Review

open access: yesAndrology, EarlyView.
ABSTRACT Background Compared with those of cytotoxic treatments, the potential effects of common medications on the fertility of men trying to conceive currently or planning to conceive in the future are less well described. The use of common medications may modify the gonadotropic axis, spermatogenesis, and epididymal maturation or alter male ...
Lina Jebli   +7 more
wiley   +1 more source

Guidelines for treatment with infliximab for Crohn's disease

open access: yes, 2006
Infliximab is an accepted induction and maintenance treatment for patients with Crohn's disease. The effectiveness of infliximab has been demonstrated for both active luminal disease and for enterocutaneous fistulisation.
Oldenburg, B.   +7 more
core   +1 more source

Infliximab treatment for steroid-refractory acute graft-versus-host disease

open access: yesHaematologica, 2004
BACKGROUND AND OBJECTIVES: Tumor necrosis factor a is one of the principal cytokines involved in the pathogenesis of acute graft-versus-host-disease (GVHD). Infliximab is an antibody to this cytokine.
F Patriarca   +12 more
doaj  

Proliferative vitreoretinopathy: An integrative, multi‐pathway perspective on pathogenesis and therapy

open access: yesActa Ophthalmologica, EarlyView.
Abstract Proliferative vitreoretinopathy (PVR) remains the principal biological cause of failed retinal detachment repair. Classical pathogenic models centred on retinal pigment epithelium (RPE) dispersion, retinal injury responses or compartment‐restricted mechanisms do not fully explain the heterogeneity, biomechanical behaviour and clinical ...
Koen A. van Overdam, J. Sebag
wiley   +1 more source

Impact of Upper Gastrointestinal Involvement on Clinical Outcomes in Paediatric Inflammatory Bowel Disease

open access: yesActa Paediatrica, EarlyView.
ABSTRACT Aim The aim of this study was to assess the clinical implications of upper gastrointestinal (UGI) involvement in paediatric inflammatory bowel disease (IBD). Methods This retrospective cohort study included children diagnosed with IBD between 2010 and 2023, who underwent a UGI endoscopic evaluation at diagnosis and were followed for at least ...
Ofek Aloni   +8 more
wiley   +1 more source

Novel approaches for drug development against chronic primary pain: A systematic review

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Chronic primary pain (CPP) persisting for more than 3 months, associated with significant emotional distress without any known underlying cause, is an unmet medical need. Traditional or adjuvant analgesics do not provide satisfactory pain relief for a great proportion of these patients.
Valéria Tékus   +5 more
wiley   +1 more source

Refining the treatment of immune checkpoint inhibitor–associated myocarditis: Challenges, innovations and rechallenge considerations

open access: yesBritish Journal of Pharmacology, EarlyView.
Immune checkpoint inhibitor (ICI)‐associated myocarditis has emerged as a severe and clinically complex immune‐related toxicity that poses significant challenges for therapeutic decision‐making in routine cardio‐oncological care. High‐dose corticosteroids remain the first‐line therapy, yet their timing, dosage and tapering require careful clinical ...
Raluca I. Mincu   +10 more
wiley   +1 more source

Economic burden of hidradenitis suppurativa based on healthcare resource utilization: German claims data analysis

open access: yesJDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background and Objectives Hidradenitis suppurativa (HS) is a chronic, debilitating skin disease affecting approximately 0.1% of the German population. Patients with HS require substantial healthcare resource utilization. This study aimed to assess the economic burden associated with HS in Germany.
Falk G. Bechara   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy